Economic/societal burden of metastatic breast cancer: A US perspective

American Journal of Managed Care

Volumn 16, Issue 9, 2010, Pages 697-704

  Allen, Jeffrey M ^a  

^a HUMANA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; GOSERELIN; IXABEPILONE; LAPATINIB; LETROZOLE; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLACEBO; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB;

ADD ON THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG TARGETING; FOLLOW UP; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITALIZATION COST; HUMAN; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SOCIOECONOMICS;

BREAST NEOPLASMS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HUMANS; NEOPLASM METASTASIS; UNITED STATES;

EID: 77957344022     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Surveillance Epidemiology and End Results. SEER stat fact sheets: breast. 2009. http://seer.cancer.gov/statfacts/html/breast.html. Accessed August 1, 2009.
2. American Cancer Society. Cancer facts & figures 2009. http://www.cancer.org/Research/CancerFactsFigures/cancer-facts-figures-2009. Accessed September 1, 2009.
3. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3(1):23-30.
4. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(suppl 3):20-29.
5. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83(1):25-32. (Pubitemid 38141890)
6. Halbert RJ, Zaher C, Wade S, Malin J, Lawless GD, Dubois RW. Outpatient cancer drug costs: changes, drivers, and the future. Cancer. 2002;94(4):1142-1150. (Pubitemid 34150870)
7. American Society of Clinical Oncology. Reimbursement for cancer treatment: coverage of off-label drug indications. J Clin Oncol. 2006;24(19):3206-3208.
8. Poole SG, Dooley MJ. Off-label prescribing in Oncology. Support Care Cancer. 2004;12(5):302-305.
9. Daniele G, Marciano R, Tortora G. The role of bevacizumab in breast cancer. Eur J Cancer Suppl. 2008;6(14):26-29.
10. Lamerato L, Havstad S, Gandhi S, Jones D, Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106(9):1875-1882. (Pubitemid 43673201)
11. Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health. 2008;11(2):213-220. (Pubitemid 351473603)
12. Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics. 2003;21(6):383-396. (Pubitemid 36461402)
13. Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics. 2009;27(3):199-209.
14. Kaiser Family Foundation. Fast facts. http://facts/kff/org/prg/chart. aspx?ch=202. Accessed February 1, 2010.
15. Neumann PJ, Sullivan SD. Economic evaluation in the US: what is the missing link? Pharmacoeconomics. 2006;24(11):1163-1168.
16. Williams I, McIver S, Moore D, Bryan S. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess. 2008;12(7):iii, ix-x, 1-175.
17. IMS Consulting. Australia's centralized cost-effectiveness requirement for pharmaceuticals: potential implications for U.S. patients. Report presented at: Cost-Effectiveness Analysis - Evidence, Economics, and Politics: Australia's Experiment in Evidence-Based Medicine; December 15, 2006; San Francisco, CA. http://www.innovation.org/index.cfm/NewsCenter/Briefings/Cost-Effectiveness- Analysis-Conference. Accessed August 1, 2009.
18. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): is economic appraisal working? Pharmacoeconomics. 2002;20(suppl 3):95-105.
19. Le QA, Hay JW. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. 2009;115(3):489-498.
20. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol. 2009;27(13):2111-2113.
21. Dedes KJ, Matter-Walstra K, Schwenkglenks M, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45(8):1397-1406.
22. Brufsky A, et al. "Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC)." J Clin Oncol. 2010;28. Abstract 1021.
23. Reed SD, Li Y, Anstrom KJ, Schulman KA. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2009;27(13):2185-2191.
24. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210-5217.
25. Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. J Manag Care Pharm. 2009;15(6):467-475.
26. Takeda AL, Jones J, Loveman E, Tan SC, Clegg AJ. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technol Assess. 2007;11(19):iii, ix-xi, 1-62.
27. Garrison LP Jr, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. 2009;12(8):1118-1123.
28. National Institute for Health and Clinical Excellence (NICE). Appraising Life-Extending, End of Life Treatments. 2008. http://www.nice.org.uk/media/88A/ F2/SupplementaryAdviceTACEoL.pdf. Accessed August 1, 2009.
29. NICE Announces Measures on End of Life Medicines, UK. Medical News Today. November 12, 2008. http://www.medicalnewstoday.com/articles/129067.php. Accessed August 1, 2009.
30. Meropol NJ, Schrag D, Smith TJ, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27(23):3868-3874.